Cardióloga, Internista, ecocardiografista, Dominicana, madre de Ethan y Lia, apasionada por la vida. Amante del corazón.
Santo Domingo, Rep. Dom.
Joined May 2014
- Tweets1.4K
- Following1.1K
- Followers412
- Likes1.9K
Ana Vergés retweeted
🆕 2026 AHA/ACC/ADA/ASN Guideline for Cardiovascular-Kidney-Metabolic Syndrome provides recommendations for the prevention, detection, evaluation, & management of interconnected CV, kidney, & metabolic disease.
More in #JACC 👉 bit.ly/4vvaJ7C #ClinicalGuidelines
Ana Vergés retweeted
Join us for this outstanding educational program on optimizing heart failure treatment, featuring a practical and innovative approach to improving patient care. #HeartFailure #Cardiology @Medscape @MedscapeES
Ana Vergés retweeted
💬 Editorial: Among patients with #HFrEF in the Veterans Health Administration, fewer than 1 in 6 achieved quadruple therapy and the median time to initiation exceeded 6 months.
ja.ma/4m04NjA
Ana Vergés retweeted
🚨 IMPEDANCE-HFpEF — #ACC26
One of the most anticipated trials delivers striking results
🔑 Noninvasive lung fluid monitoring:
• ↓ 81% HF hospitalizations
• ↓ 65% all-cause mortality
• Earlier and more frequent treatment adjustments
🧠 Detecting congestion before symptoms may change how we manage HFpEF – at New Orleans, LA
Ana Vergés retweeted
Dominican Republic contributing a grain of sand in global research @ACCinTouch
Congress 2025 @JACCJournals
Thanks to my research team !
@society_eas
@atherosociety
#ACC25 #ACCPrev
Links bellow
lnkd.in/eMXpfUhP
lnkd.in/erDpckjC
lnkd.in/eDZ3-KRD
Ana Vergés retweeted
Congratulations to our co-founder @Drroxmehran on becoming President of @ACCinTouch!
This milestone reflects her leadership, impact and commitment to advancing equity. She opens doors, elevates voices, & reshapes what's possible for women in cardiology!
#ACC26
ALT Headshot of Dr Roxana Mehran. Text reads: Congratulations to the new ACC President, Roxana Mehran, MD, FACC.
Ana Vergés retweeted
🟢Kerendia™ (finerenone) approved in 🇪🇺
is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate statistically significant and clinically meaningful cardiovascular benefits in a Phase III study in patients with HF with LVEF ≥40%
Ana Vergés retweeted
Beyond the sessions,
this is where leadership connects.
⭐ #ACC26
Sharing perspectives with researchers and leaders who have shaped modern cardiovascular prevention.
Because advancing the field requires more than data.
It requires collaboration.
@ACCinTouch @JACCJournals
Ana Vergés retweeted
🫀 Webinar Comorbilidades de la Insuficiencia Cardíaca
Te invitamos a participar de un nuevo encuentro virtual organizado por CIFACAH y SODOCARDIO, dedicado a profundizar en las principales comorbilidades asociadas a la insuficiencia cardíaca.
📅 Martes 11 de noviembre de 2025
🕖 Horarios: 17 h 🇲🇽 🇨🇷 | 18 h 🇵🇪 🇪🇨 🇨🇴 | 19 h 🇻🇪 🇩🇴 | 20 h 🇺🇾 🇦🇷 🇧🇷 🇵🇾 🇨🇱
🎓 Temas destacados:
- Caso clínico – Dra. Eunices Tavárez Castillo
- Insuficiencia cardíaca y enfermedad renal crónica – Dr. Enrique Fairman
- Falla cardíaca en el anciano – Dr. Alex Rivera Toquica
- Ferropenia en el paciente con insuficiencia cardíaca – Dra. Ana Vergés Castro
👩⚕️ Coordinan: Dra. Vizmary Pineda y Dra. Bernardita González Zúñiga
💬 Con la participación de los Dres. Edisson Feliz y Edgar Cadena en el panel de expertos.
🔗 Inscripción gratuita en siacardio.com/webinarcifacah…
Mañana nuestro webinar conjunto SODOCARDIO y CIFACAH: comorbilidades en IC. Imperdible!!
siacardio.com/webinarcifacah…
Ana Vergés retweeted
Atención!
Próximo martes 11 de Noviembre!
Nuevo webinar @cifacah , esta vez junto a @sodocardio1
No se lo pierdan! 🫀🙌🏻
Ana Vergés retweeted
🗞️ Future development of arrhythmogenic risk scores in patients with #HeartFailure & inherited dilated cardiomyopathy.
A scientific statement of the #HFA of @escardio
@ESC_Journals @GiuseppeGalati_
@AmrAbdin10 @HanCardiomd
@HFA_President
bit.ly/48AjyVL
Ana Vergés retweeted
Ready to grow your network? 🩺
Join The Pulse, complete your profile, explore Groups and the Live Feed, and connect with thousands of women in cardiology worldwide.
Get started: womenasonepulse.org
#CardioTwitter #WIC @Drroxmehran @drmalissawood
Ana Vergés retweeted
Maternal #HeartFailure, lessons from Sweden🫀:
A nationwide, population-based study (2000–2019) involving >2 million deliveries found:
📍66% ⬆️ in maternal HF incidence
📍0.34 cases per 1,000 deliveries
📍~50% with associated cardiac disease
📍some risk factors: 🤰maternal age > 35, #hypertension, multiple gestation, & hypertensive disorders of pregnancy
👉While rising comorbidities explain part of this trend, the growing burden of maternal #HF remains a clinical concern.
👉Early recognition, prevention, & coordinated care are essential
More in @JACCJournals #JACCHF: jacc.org/doi/10.1016/j.jchf.…
#CardioOB #CardioObstetrics @CardioOb #ACCCardioOB
Ana Vergés retweeted
New chapter published in the book 📘
"Pathogenesis of subclinical atherosclerosis" - SIAC 2026.
We explore how inflammation, endothelial dysfunction and the NLRP3 inflammasome drive atherosclerotic progression from early stages.
Méndez Castillo M, Alonso R, Salgueiro J.
Ana Vergés retweeted
From the latest 2025 #ESCGuidelines for the management of #CVdisease in pregnancy:
💊Choices of medications use during Pregnancy & during lactation+breastfeeding
Full paper @ehj_ed #EHJ: doi.org/10.1093/eurheartj/eh…
@escardio @ESC_Journals #ESCCongress
@CardioOb #CardioObstetrics
Ana Vergés retweeted
📍
#ChagasDisease
At last a well designed randomized clinical trial!
After these results, would you change from enalapril to SacVal? (Remember these are poor people 7million mainly in rural LatAm and cost of SacVal is much higher than ENL)
Disclosure: I would!
Ana Vergés retweeted
New State-of-the-Art in @JACCJournals
Aldosterone is assaulting patients with HF/CKM!!!
Where do steroidal and nonsteroidal MR antagonism overlap—and diverge—in HF?
sMRAs = Class I in HFrEF but limited by hyperK/endocrine AEs;
nsMRA shows CV/renal benefit in CKD+T2D and reduces HF events in HFmrEF/HFpEF (FINEARTS-HF).
What’s next? Role for HFrEF, implementation/uptake, cost-effectiveness; plus MR modulators & aldosterone synthase inhibitors on the horizon.
Open access.
doi.org/10.1016/j.jchf.2025.…
